Cita APA

Peñalver, F., Márquez, J., Durán, S., Giraldo, P., Martín, A., Montalbán, C., & López Hernández, A. (2019). Response‐adapted treatment with rituximab, bendamustine, mitoxantrone, and dexamethasone followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma after first‐line immunochemotherapy: Results of the RBMDGELTAMO08 phase II trial.

Citación estilo Chicago

Peñalver, Francisco‐Javier, Jose‐Antonio Márquez, Soledad Durán, Pilar Giraldo, Alejandro Martín, Carlos Montalbán, y Andrés López Hernández. Response‐adapted Treatment With Rituximab, Bendamustine, Mitoxantrone, and Dexamethasone Followed By Rituximab Maintenance in Patients With Relapsed or Refractory Follicular Lymphoma After First‐line Immunochemotherapy: Results of the RBMDGELTAMO08 Phase II Trial. 2019.

Cita MLA

Peñalver, Francisco‐Javier, et al. Response‐adapted Treatment With Rituximab, Bendamustine, Mitoxantrone, and Dexamethasone Followed By Rituximab Maintenance in Patients With Relapsed or Refractory Follicular Lymphoma After First‐line Immunochemotherapy: Results of the RBMDGELTAMO08 Phase II Trial. 2019.